{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:51:49Z","timestamp":1781909509874,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"DOI":"10.7759\/cureus.111169","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:08:24Z","timestamp":1781906904000},"source":"Crossref","is-referenced-by-count":0,"title":["Normal Ovarian Reserve During Long-Term Osimertinib Therapy in a Patient With Li-Fraumeni Syndrome: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Sana M","family":"Salih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Atmakuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma Z","family":"Elsarrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay F","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen P","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021, 20:551-69. 10.1038\/s41573-021-00195-4","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam SS","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al.. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020, 382:41-50. 10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deq212","article-title":"Human oocyte maturation is dependent on LH-stimulated accumulation of the epidermal growth factor-like growth factor, amphiregulin","volume":"25","author":"Zamah AM","year":"2010","unstructured":"Zamah AM, Hsieh M, Chen J, Vigne JL, Rosen MP, Cedars MI, Conti M. Human oocyte maturation is dependent on LH-stimulated accumulation of the epidermal growth factor-like growth factor, amphiregulin. Hum Reprod. 2010, 25:2569-78. 10.1093\/humrep\/deq212","journal-title":"Hum Reprod"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.08.017","article-title":"DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa","volume":"48","author":"Kerr JB","year":"2012","unstructured":"Kerr JB, Hutt KJ, Michalak EM, et al.. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol Cell. 2012, 48:343-52. 10.1016\/j.molcel.2012.08.017","journal-title":"Mol Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.02.005","article-title":"A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept","volume":"105","author":"Alviggi C","year":"2016","unstructured":"Alviggi C, Andersen CY, Buehler K, et al.. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016, 105:1452-3. 10.1016\/j.fertnstert.2016.02.005","journal-title":"Fertil Steril"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a002576","article-title":"Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner","volume":"4","author":"Cotter JA","year":"2018","unstructured":"Cotter JA, Szymanski L, Karimov C, et al.. Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner. Cold Spring Harb Mol Case Stud. 2018, 4:a002576. 10.1101\/mcs.a002576","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.01.003","article-title":"Lung cancer oncogene-directed therapy, fertility, and pregnancy","volume":"19","author":"Simons E","year":"2024","unstructured":"Simons E, Camidge DR. Lung cancer oncogene-directed therapy, fertility, and pregnancy. J Thorac Oncol. 2024, 19:866-76. 10.1016\/j.jtho.2024.01.003","journal-title":"J Thorac Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Chaft JE","year":"2011","unstructured":"Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res. 2011, 17:6298-303. 10.1158\/1078-0432.CCR-11-1468","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi M","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, et al.. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023, 389:137-47. 10.1056\/NEJMoa2304594","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.03.016","article-title":"Is ALK inhibitor a contraindication for subsequent IVF pregnancy?","volume":"14","author":"Gillis R","year":"2019","unstructured":"Gillis R, Meirovitz M, Ben David Hadani M, Hourvitz A, Peled N. Is ALK inhibitor a contraindication for subsequent IVF pregnancy?. J Thorac Oncol. 2019, 14:e176-8. 10.1016\/j.jtho.2019.03.016","journal-title":"J Thorac Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.08.011","article-title":"Ovarian stimulation in young adult cancer survivors on targeted cancer therapies","volume":"106","author":"Su HI","year":"2016","unstructured":"Su HI, Connell MW, Bazhenova LA. Ovarian stimulation in young adult cancer survivors on targeted cancer therapies. Fertil Steril. 2016, 106:1475-8. 10.1016\/j.fertnstert.2016.08.011","journal-title":"Fertil Steril"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/life13051209","article-title":"The impact of systemic oncological treatments on the fertility of adolescents and young adults - a systematic review","volume":"13","author":"Himpe J","year":"2023","unstructured":"Himpe J, Lammerant S, Van den Bergh L, Lapeire L, De Roo C. The impact of systemic oncological treatments on the fertility of adolescents and young adults - a systematic review. Life (Basel). 2023, 13:1209. 10.3390\/life13051209","journal-title":"Life (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152872","article-title":"The tyrosine kinase inhibitor sunitinib affects ovulation but not ovarian reserve in mouse: a preclinical study","volume":"11","author":"Bernard V","year":"2016","unstructured":"Bernard V, Bouilly J, Kramer P, et al.. The tyrosine kinase inhibitor sunitinib affects ovulation but not ovarian reserve in mouse: a preclinical study. PLoS One. 2016, 11:e0152872. 10.1371\/journal.pone.0152872","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-020-01778-7","article-title":"Long-term imatinib diminishes ovarian reserve and impacts embryo quality","volume":"37","author":"Salem W","year":"2020","unstructured":"Salem W, Ho JR, Woo I, Ingles SA, Chung K, Paulson RJ, McGinnis LK. Long-term imatinib diminishes ovarian reserve and impacts embryo quality. J Assist Reprod Genet. 2020, 37:1459-66. 10.1007\/s10815-020-01778-7","journal-title":"J Assist Reprod Genet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7660","article-title":"Lapatinib\u2011induced inhibition of ovarian function is counteracted by the STAT3 pathway both in\u00a0vivo and in\u00a0vitro","volume":"44","author":"Liao Q","year":"2020","unstructured":"Liao Q, Feng X, Li X, et al.. Lapatinib\u2011induced inhibition of ovarian function is counteracted by the STAT3 pathway both in\u00a0vivo and in\u00a0vitro. Oncol Rep. 2020, 44:1127-35. 10.3892\/or.2020.7660","journal-title":"Oncol Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7065","article-title":"Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer","volume":"21","author":"Lambertini M","year":"2023","unstructured":"Lambertini M, Ceppi M, Anderson RA, et al.. Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer. J Natl Compr Canc Netw. 2023, 21:33-41.e16. 10.6004\/jnccn.2022.7065","journal-title":"J Natl Compr Canc Netw"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602585","article-title":"Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients","volume":"92","author":"Nishio M","year":"2005","unstructured":"Nishio M, Ohyanagi F, Horiike A, et al.. Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. Br J Cancer. 2005, 92:1877-80. 10.1038\/sj.bjc.6602585","journal-title":"Br J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1108124","article-title":"Case report: osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer","volume":"13","author":"Soberanis Pina P","year":"2023","unstructured":"Soberanis Pina P, Lara-Mej\u00eda L, Matias-Cruz V, et al.. Case report: osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer. Front Oncol. 2023, 13:1108124. 10.3389\/fonc.2023.1108124","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.09.001","article-title":"Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma","volume":"161","author":"Boudy AS","year":"2021","unstructured":"Boudy AS, Grausz N, Selleret L, et al.. Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma. Lung Cancer. 2021, 161:68-75. 10.1016\/j.lungcan.2021.09.001","journal-title":"Lung Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6091","article-title":"Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma\/pheochromocytoma and smooth muscle tumors","volume":"6","author":"Hoekstra AS","year":"2015","unstructured":"Hoekstra AS, de Graaff MA, Briaire-de Bruijn IH, et al.. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma\/pheochromocytoma and smooth muscle tumors. Oncotarget. 2015, 6:38777-88. 10.18632\/oncotarget.6091","journal-title":"Oncotarget"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503764-normal-ovarian-reserve-during-long-term-osimertinib-therapy-in-a-patient-with-li-fraumeni-syndrome-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:08:25Z","timestamp":1781906905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503764-normal-ovarian-reserve-during-long-term-osimertinib-therapy-in-a-patient-with-li-fraumeni-syndrome-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.111169","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}